Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Alexion Pharmaceuticals, Inc.
Study ID
NCT05966467
Status
Recruiting
Apply to this trial

Conditions

  • AQP4+ NMOSD
  • NMOSD
  • Neuromyelitis Optica Spectrum Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.

Key Dates

Start date
Feb 1, 2024
Status verified
Feb 2026
Primary completion
Mar 1, 2030
Completion
Mar 1, 2030

Study Design

Enrollment
122 participants (estimated)

Primary Outcome Measure

Annualized Relapse Rate (ARR) [ Time Frame: Up to approximately 5 years ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Clinical Trial SiteWashington D.C.District of Columbia20010
Benjamin Osborne
Research SiteBostonMassachusetts02114-
Clinical Trial SiteChapel HillNorth Carolina27599
Irena Dujmovic-Basuroski
Clinical Trial SiteColumbusOhio43215
Jacqueline Nicholas
Clinical Trial SitePlanoTexas75024
Annette Okai
Clinical Trial SiteMilwaukeeWisconsin53215
Bhupendra Khatri

Find similar trials in Washington D.C., DC

By research site
Clinical Trial Site· Washington D.C., DCResearch Site· Boston, MAClinical Trial Site· Chapel Hill, NCClinical Trial Site· Columbus, OHClinical Trial Site· Plano, TXClinical Trial Site· Milwaukee, WI

Related Studies